DVAX + 8 % en Pre Market
FDA queries Dynavax on Heplisav-B marketing application; PDUFA date remains December 15
http://seekingalpha.com/news/3211933-fda-queries-dynavax-heplisav-b-marketing-application-pdufa-date-remains-december-15?source=email_rt_mc_readmore&app=1&uprof=37#email_link
MACK
Announces Major Corporate Restructuring. CEO resigns. 22% workforce reduction
http://investors.merrimack.com/releasedetail.cfm?ReleaseID=991771
NVAX
En la pre 2.15 eso sí con volumen ridiculo
Lo fácil es culpar a otros o a la mala suerte... en vez de al poco cuidado
NVAX
Me había quedado la contestación esta pendiente
La fase III del Resolve y la fase II Rollover pone "observer blinded" en la página de NVAX.
Phase 3 Resolve™ Trial
The trial was a randomized, observer-blinded, placebo-controlled trial conducted at 60 sites in the United States. The primary objective of the Resolve trial was to demonstrate efficacy in the prevention of moderate-severe RSV-associated lower respiratory tract disease (RSV msLRTD), as defined by the presence of multiple lower respiratory tract symptoms
Phase 2 Rollover Trial
Novavax also reported topline results from the Phase 2 rollover clinical trial of its RSV F Vaccine in older adults.
The trial was a randomized, observer-blinded, placebo-controlled rollover trial which enrolled 1,329 older adults from the prior Phase 2 trial, conducted at the same 10 sites in the United States.
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArticle&ID=2202271
«Después de nada, o después de todo/ supe que todo no era más que nada.»
CPRX
Sobre los 10 días alcanzados sobre $1 para seguir en NASDAQ:
http://ir.catalystpharma.com/secfiling.cfm?filingid=1193125-16-728689&CIK=1369568
ARNA
Subida inicial por comercialización de la dosis extendida. Ahora sale esta otra noticia sobre demanda a la empresa que presentó la solicitud de genérico en agosto.
filed a patent infringement lawsuit against Lupin Limited and Lupin Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware in response to a “Paragraph IV certification” notification received from Lupin Limited in August 2016. The notification advised that Lupin Limited submitted an abbreviated new drug application (ANDA) requesting approval to engage in the commercial manufacture, use, importation, offer for sale or sale of a generic version of BELVIQ® (lorcaserin hydrochloride tablets, 10 mg).
http://invest.arenapharm.com/secfiling.cfm?filingid=1564590-16-25561&CIK=1080709
«Después de nada, o después de todo/ supe que todo no era más que nada.»
NVAX
Respecto al "Harami bajista" en semanal. Tal y como pone en el texto que añades:
"El cuerpo de la segunda vela queda totalmente envuelto por la vela anterior"
Que siendo estrictos no es el caso.
Tengo que mirarla con buenos ojos, es lo que me queda.
Paciencia.
Es difícil tenerla, pero trae muy buenos resultados.....
